Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201–995
- 1 January 1988
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 66 (2) , 75-77
- https://doi.org/10.1007/bf01713015
Abstract
A 53-year-old man with metastatic ileal carcinoid ultimately failed to respond to conventional measures of surgery and was finally treated with a new long acting somatostatin analogue, SMS 201–995 for 7 months. SMS 201–995 not only gave symptomatic relief but also induced a reduction in metastatic tumor mass.This publication has 14 references indexed in Scilit:
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- Somatostatin Localization in TissuesScandinavian Journal of Gastroenterology, 1986
- Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.Gut, 1985
- Effect of a Long-Acting Somatostatin Analogue (SMS 201–995) in a Patient with Pancreatic CholeraNew England Journal of Medicine, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic choleraDigestive Diseases and Sciences, 1982
- Colorimetric assay of urinary 5-hydroxy-3-indoleacetic acidClinical Biochemistry, 1982
- Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.Gut, 1981
- Metabolic Clearance and Plasma Half-Disappearance Time of Exogenous Somatostatin in Man*Journal of Clinical Endocrinology & Metabolism, 1979
- The Carcinoid FlushNew England Journal of Medicine, 1978